NextCure, Inc. NXTC
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -55.53%
- 1 year
- -48.49%
- Open
- 6.32
- Prev close
- 6.53
- Mkt cap
- 28.88M
- Vol
- 19.20K
- Avg vol
- 152.91K
- EPS
- -8.71
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.24
- High
- 6.58
- Forward P/E
- -0.66
- Beta
- 0.79
- Short ratio
- 1.89
- Inst. own
- 57.52%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 1, 2024
- 50-d avg
- 1.25
- 200-d avg
- 1.49
- 1y target
- 3.33
Key statistics
- Market cap
- 26.35M
- Enterprise value
- -43.22M
- Trailing P/E
- 0.00
- Forward P/E
- -0.66
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.23
- EPS (TTM)
- -2.10
- Beta
- 0.79
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -26.33M
- Total cash
- 86.44M
- Total debt
- 6.29M
- Return on equity
- -54.74%
- Shares outstanding
- 28.01M
- Short % of float
- 0.28%
- 50-day average
- 1.25
- 200-day average
- 1.49
Analyst view
Consensus: none
- Target (low)
- 3.00
- Target (mean)
- 3.33
- Target (high)
- 4.00
- Strong buy3
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 1, 2024
Expected Aug 1, 2024. Consensus EPS estimate -0.375.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.35 | -0.41 | -0.06 | -17.14% |
| Aug 1, 2024 | Jun 1, 2024 | -0.36 | -0.55 | -0.19 | -52.78% |
| Aug 1, 2024 | Jun 1, 2024 | -0.36 | — | — | — |
| May 2, 2024 | Mar 1, 2024 | -0.45 | -0.61 | -0.16 | -35.56% |
| May 2, 2024 | Mar 1, 2024 | -0.45 | — | — | — |
| Mar 21, 2024 | Dec 1, 2023 | -0.54 | -0.52 | +0.02 | +3.70% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 2, 2024 | Needham | reit | Buy | Buy |
| Jun 3, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 31, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 3, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 3, 2024 | Needham | reit | Buy | Buy |
About NextCure, Inc.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- nextcure.com
News
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- 12 Health Care Stocks Moving In Friday's After-Market Session
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- NextCure (NASDAQ:NXTC) Stock Price Up 7.7% – Time to Buy?
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001
- 12 Health Care Stocks Moving In Friday's After-Market Session
- NextCure Q2 EPS $(2.80) Misses $(1.94) Estimate
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
Your note
Sign in to keep a note on NXTC — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sofinnova Investments, Inc. | 9.54% | 2,671,856 | 2.51M | Sep 29, 2024 |
| Logos Global Management LP | 8.93% | 2,500,000 | 2.35M | Sep 29, 2024 |
| Affinity Asset Advisors, Llc | 8.22% | 2,302,598 | 2.17M | Sep 29, 2024 |
| Orbimed Advisors LLC. | 4.07% | 1,141,200 | 1.07M | Sep 29, 2024 |
| Vanguard Group Inc | 3.53% | 987,324 | 929.07K | Sep 29, 2024 |
| Blackrock Inc. | 2.61% | 729,836 | 686.77K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.19% | 613,827 | 577.61K | Sep 29, 2024 |
| Federated Hermes MDT Mid Cap Growth Fund | 1.13% | 315,180 | 296.58K | Jul 30, 2024 |
| Vanguard Extended Market Index Fund | 0.72% | 201,978 | 190.06K | Sep 29, 2024 |
| Vanguard Explorer Fund, Inc. | 0.61% | 171,519 | 161.40K | Jul 30, 2024 |
| BlackRock Advantage Small Cap Core Fund | 0.61% | 169,789 | 159.77K | Aug 30, 2024 |
| Delaware Group Equity Fds IV-Delaware Healthcare Fund | 0.54% | 150,000 | 141.15K | Sep 29, 2024 |